EP2753187
METHOD FOR PREVENTING AND/OR TREATING INSULIN RESISTANCE
Mit der Maus auf einen Inhaber zeigen, um die Daten zu sehen
- Caelus Pharmaceuticals B.V.; Stichting Amsterdam UMCseit 16. Feb. 2024
- Caelus Pharmaceuticals B.V.; Academisch Medisch Centrum11. Juli 2014 – 16. Feb. 2024
- Academisch Medisch Centrum; Wageningen Universiteit13. Juni 2014 – 11. Juli 2014
The present invention describes use of Eubacterium hallii etrel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria, as a medicament, in particular for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitusas well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes)in a subject in need thereof, said method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
Aus der internationalen Anmeldung WO2013032328
| Datum | Verfahren | Kammer | Art | Ergebnis | Parteien |
|---|---|---|---|---|---|
| 11. Mai 2026 | UPC CFI 1615/2026 | The Hague LD | Einstweilige Verfügung | Gesperrt | CAELUS LIFESCIENCES IP B.V. +5 |
Weitere Verfahren zu diesem Patent